Tag:
Cephalon
Latest Headlines
Latest Headlines
With Provigil exclusivity, Teva may hike its forecast
Teva can reap sales of branded Provigil, and it can profit from the generic version.
Teva looks set for a new round of M&A deals
Don't be too surprised if Teva starts to make fresh headlines on the M&A side of the business. CEO Shlomo Yanai is telling reporters the company is acutely aware of just how badly it needs to
Teva's Cephalon recalls leukemia drug over fragments in vial
Teva Pharmaceutical Industries' ( $TEVA ) Cephalon has recalled one lot of leukemia drug Treanda after glass fragments were found in one of the vials. FDA-approved labeling for Treanda states that...
Actavis CEO: Today's generics business is doomed
Actavis CEO Claudio Albrecht sees the end of the world as we know it—the generics world, that is. The copycat-drugs business is transforming. Boundaries are changing. To stay ahead of those
Teva jacks up prices on Cephalon legacy brands
Here's one way to increase your drug sales overnight: First, buy a company. Then, raise its product prices up to 25%. That, apparently, is Teva Pharmaceutical Industries' ( $TEVA ) strategy for
Mesoblast's Revascor demonstrates blockbuster potential in small CHF study
Mesoblast is taking center stage today at the American Heart Association's annual meeting with some impressive new data from a small mid-stage study of its stem cell therapy--Revascor--for heart
Teva: 'Too early' to say whether merger triggers job cuts
Teva Pharmaceutical Industries ( $TEVA ) says recent reports of up to 1,500 job cuts from the integration of its recent acquisition, Cephalon , "came from unsubstantiated sources." A U.S. spokeswoman
Integrating Cephalon, Teva eyes up to 1,500 job cuts
Hard on the heels of its merger with Cephalon , Teva Pharmaceutical Industries ( $TEVA ) is sharpening its jobs axe. Israeli news sources report anywhere from 1,000 to 1,500 cuts, with most of the
Teva wraps Cephalon buy, agrees to sell Provigil copy
Good news for Teva Pharmaceutical Industries ( $TEVA ): It's wrapped up its $6.2 billion merger with Cephalon ( $CEPH ). European Union authorities gave the go-ahead for the deal just a few days after
Teva sells rights to gain FTC nod for Cephlon deal
Teva Pharmaceutical Industries ( $TEVA ) has won regulatory approval for its proposed $6.2 billion merger with Cephalon--on a few conditions, that is. The company agreed to sell off the rights to
